| Autor: |
Giuseppina Amarù, Lara Scoppapietra, Cristina Crocillà, Marika Salafia, Mara Finotti, Vittorio Schiavo, Valentino Granero |
| Jazyk: |
English<br />Italian |
| Rok vydání: |
2022 |
| Předmět: |
|
| Zdroj: |
Microbiologia Medica, Vol 37, Iss 1 (2022) |
| Druh dokumentu: |
article |
| ISSN: |
2280-6423 |
| DOI: |
10.4081/mm.2022.10405 |
| Popis: |
Background and aims: Meropenem (Mer) and vaborbactam (Vab) is a combination of a carbapenem and a new β-lactamase inhibitor used in adults to treat different types of infections caused by Gram-negative bacteria. This combination is chosen as an alternative in infections caused by Gram-negative bacteria when carbapenem-only therapies are unsatisfactory. Materials and methods: Based on this, we report our assessment of such meropenem/vaborbactam association through the E-test and the Microscan routine automated system. This evaluation was performed on 22 samples, carbapenem-resistant strains of Gram-negative bacteria isolated from different types of biological material. Five E. coli and 1 P. mirabilis were respectively susceptible to both carbapenems and Mer/Vab, 6 P. aeruginosa and 2 A. baumannii were respectively resistant to both carbapenems and Mer/Vab and out of 8 K. pneumoniae which were resistant to carbapenems only one was resistant to the Mer/Var combination. Results and conclusions: From the data obtained, it can be seen that resistance to carbapenems is 72%, and drops to 36% with the combined use of Mer/Vab. However, this combination cannot be used in the treatment of patients with diseases caused by P. aeruginosa and Acinetobacter spp., resistant to meropenem. |
| Databáze: |
Directory of Open Access Journals |
| Externí odkaz: |
|
